In the latest edition of the Sharesify Podcast, Ian and James discuss why markets remain difficult for investors to navigate due to the ‘tape bombs’ emanating from the White House. While the FTSE 100 has resurfaced above the 10,000 level, the FTSE 250 has been slower to recover.
On the earnings front, James addresses the Middle East challenges facing protein powders-to-supplements firm Applied Nutrition (APN) and highlights this week’s fresh £300 million buyback from DIY retailer Kingfisher (KGF). The FTSE 100 retailer’s B&Q and Screwfix chains are on solid foundations but the French market remains a drag.
Ian shines the spotlight on insurance-to-workplace benefits business Personal Group (PGH:AIM), which smashed it in 2025 and is sticking to its 2030 targets. Heading in the oppositive direction was Goodwin (GDWN), the family-controlled engineer which plunged on fears it may have to suspend production. Ian reckons many retail holders have moved on and marched their money into fantasy miniatures maker Games Workshop (GAW) instead.
Finally, James looks forward to our upcoming Podcast specials with investment trusts AVI Japan Opportunity (AJOT), MIGO Opportunities (MIGO) and Law Debenture (LWDB).
How you can get involved
If you’d like us to discuss a particular topic, feel free to email us your thoughts and suggestions at editorial@sharesify.com. For those tuning in via YouTube, please remember to click the Like and Subscribe buttons on our channel.
You can also follow us on X, Bluesky, Facebook or LinkedIn.
And if you are a company, a fund or investment trust and you’d like to join us on the podcast, tell your story and expand your retail investor base, here’s your chance. Just email us at editorial@sharesify.com and we’ll do the rest.
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
